Syros Pharmaceuticals, Inc.
syros.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q3 FY2024 10-Q, filed Oct 31, 2024. Its latest SEC filing is a SCHEDULE 13D/A from Mar 27, 2025.
10-Q for Q3 FY2024, filed Oct 31, 2024
The sections below describe the company as of the FY2023 annual report.
What Did They Do?
Develops tamibarotene, a cancer drug candidate for patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia.
10-K for FY2023, filed Mar 27, 2024We are a biopharmaceutical company committed to developing new standards of care for the frontline treatment of patients with hematologic…View ↗
How Did They Make Money?
Partners pay upfront license fees or prepay research, and agreements may include development milestones and royalties on licensed-product sales; Syros earns revenue for research as it performs the services.
10-K for FY2023, filed Mar 27, 2024
$9.9M
-
10-K for FY2023, filed Mar 27, 2024
$9.9M ↗
Who Were Their Customers?
Drug-company partners collaborate with Syros on research and target discovery; agreements can include research funding and options to license resulting compounds.
10-K for FY2023, filed Mar 27, 2024On December 17, 2019, the Company entered into a license and collaboration agreement (the “GBT Collaboration Agreement”) with Global Blood…View ↗
Pursuant to the terms of the GBT Collaboration Agreement, GBT paid the Company an upfront payment of $20.0 million. GBT also agreed to…View ↗
The Company granted to GBT an option (the “Option”) to obtain an exclusive, worldwide license, with the right to sublicense, under relevant…View ↗
Agreement with Incyte CorporationView ↗
The Company identified a single performance obligation which included (i) a research license that Incyte retained as long as there remained…View ↗
Did Revenues Turn Into Profits?
No. It lost $164.6M in FY2023.
10-K for FY2023, filed Mar 27, 2024
−$129MView ↗
10-K for FY2023, filed Mar 27, 2024
−$164.6MView ↗
10-K for FY2023, filed Mar 27, 2024
−$110MView ↗
How Were They Changing?
- Net income
-
Sources
10-Q for Q3 FY2024, filed Oct 31, 2024
−$6.4MView ↗
- ▼ −84% (Loss)
- vs −$40.1M in Q3 FY2023
-
Mar 4, 2025
Syros paid off its loan obligations
The lenders accepted cash and other assets toward the payoff.
Sources
8-K, filed Mar 4, 2025
On February 28, 2025, Syros Pharmaceuticals, Inc. (the “Company”) entered into a letter agreement with Oxford Finance LLC (“Oxford”), which…View ↗
-
Feb 28, 2025
Plans to delist its stock; CEO leaves
Syros also agreed to wind down operations and limit spending under an Oxford-approved budget.
Sources
8-K, filed Feb 28, 2025
On February 28, 2025, the Board of Directors (the “Board”) of Syros Pharmaceuticals, Inc. (the “Company”) approved the voluntary delisting…View ↗
-
Nov 13, 2024
SELECT-MDS-1 missed its primary endpoint
Syros said it would stop the study, review the full data and evaluate next steps.
Sources
8-K, filed Nov 13, 2024
CAMBRIDGE, Mass.—(BUSINESS WIRE)— Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of…View ↗
-
Aug 12, 2024
Syros stopped enrollment in SELECT-AML-1
After an interim analysis found similar response rates in the two arms, the company said the study was unlikely to show superiority.
Sources
8-K, filed Aug 12, 2024
CAMBRIDGE, Mass., August 12, 2024 – Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards…View ↗
Grew. Revenue grew 5.0x in 4 years, from $2M in FY2019 to $9.9M in FY2023, about 50% a year.
Who Did They Compete With?
Competes with Abbvie, Roche Holding, Taiho Oncology, and Pfizer
10-K for FY2023, filed Mar 27, 2024We are developing tamibarotene, our RARα agonist, for patients with AML and MDS. We are selecting patients for our clinical trials based on…View ↗
Loading...
